IP37: Prostate Cancer: Localized: Ablative Therapy II
Saturday, May 16, 2026 1:00 PM to 3:00 PM · 2 hr. (America/New_York)
145AB
Poster and Podium Sessions
Oncology: Prostate
Saturday, May 16
IP37-01: 10-year oncological outcomes following focal HIFU and cryotherapy for treatment of non-metastatic prostate cancer: An analysis of 3471 patients from the prospective HEAT and ICE registries
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-02: Comparison of contemporary patient selection criteria for focal therapy: An analysis of 2658 patients from the prospective HEAT and ICE registries
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-03: 7-year oncological outcomes following focal cryo-ablation for the treatment of intermediate favorable risk prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-04: One consensus, many perspectives: exploring demographic variability in the FALCON study
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-05: A multi-institution analysis of oncological and safety outcomes following focal therapy in the USA
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-06: Real-World Surveillance Patterns Following Focal Therapy for Localized Prostate Cancer: A National Claims Analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-07: Hemigland vs. Whole Gland Primary Cryoablation for Localised Prostate Cancer: a Comparative Analysis Evaluating Perioperative, Oncological, and Functional Outcomes
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
Leonardo Misuraca
IP37-08: Safety and functional outcomes of focal salvage cryoablation of the prostate in patients with prior external-beam radiation therapy
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-09: Pre-Salvage PSMA PET/CT Utilization and Prognostic Value in a Contemporary Salvage Cohort
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-10: “Too Late to Fall”: Prolonged PSA Nadir as a Marker of Early Oncologic Failure after Cryoablation and HIFU for localized prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
Umberto Anceschi · IRCSS "regina Elena" National Cancer Institute
IP37-11: Propensity Score Matched Analysis: focal therapy compared to robot assisted radical prostatectomy for localized prostate cancer.
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-12: Functional and early oncologic outcomes of salvage robotic assisted radical prostatectomy after high intensity focused ultrasound prostate ablation: a multicentre study
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
Giuseppe Chiacchio
IP37-13: Multicenter registry of MRI-guided transurethral ultrasound ablation (TULSA): MRI characteristics associated with treatment outcome
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-14: Morphologic and perfusion changes induced by short-term neoadjuvant androgen deprivation therapy before MRI-guided transurethral ultrasound ablation for localized prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-15: Transurethral Ultrasound Ablation of the Prostate Is Effective for Localized Prostate Cancer and Functional Preservation: Single-Center Real World Data
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-16: Lesion-targeted MRI-guided transurethral ultrasound ablation for localized prostate cancer: 12-month safety, efficacy, and functional outcomes from a phase 2 trial
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-17: Post-Focal Therapy Surveillance: The Role of PSMA PET and MRI After Irreversible Electroporation
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-18: Lower Urinary Tract Symptom Improvement After Focal Irreversible Electroporation for Localized Prostate Cancer: 12-Month PRESERVE Trial Results
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-19: Impact of irreversible electroporation on sexual function: an analysis of the PRESERVE Trial
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-20: Salvage irreversible electroporation after radiation therapy for recurrent prostate cancer: a multi-institutional real-world experience
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-21: Combination of PSA kinetics and MRI for the diagnosis of Persistent Prostate Cancer following Irreversible Electroporation Focal Therapy
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-22: An open-label Phase I/II study to assess the safety and efficacy of photodynamic therapy using the SpectraCure P18 System with verteporfin for the treatment of recurrent prostate cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-23: Can microwave focal ablation treat Grade Group 4 prostate cancer?
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-24: Validation of the ePI-FAB Score to Predict Residual Disease Following Cooled Focal Laser Ablation with ProFocalTM in Prostate Cancer
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
Ymer Bushati
IP37-26: Water Vapor Therapy for The Management of Prostate Cancer: The VAPOR 2 Study Initial Report
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-27: Intravenous Tranexamic Acid to Reduce Perioperative Bleeding in Waterjet Ablation of the Prostate: A Prospective Randomized Trial
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-28: ?Can we avoid contralateral biopsies when considering focal therapy? What may we miss?
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-29: Focal Therapy vs Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer: A Systematic Review, Meta-Analysis, and Bayesian Network Analysis
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB
IP37-30: Functional and Perioperative Outcomes of High-Intensity Focused Ultrasound Therapy: A Comparison with Single-Port Transvesical and Multi-Port Transperitoneal Approaches
Saturday, May 16, 2026 1:00 PM to 3:00 PM
145AB